Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.
1:15-cv-00277
Overview
Parties
Defendant
Plaintiff
Merck Patent Gesellschaft mit beschrankter Haftung NPE (University / Research)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Merck KGaA Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Forest Laboratories Holdings Ltd. NPE (Patent Assertion Entity)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Forest Laboratories LLC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 17 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 7,834,020 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,981,894 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,193,195 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011018399 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,318,744 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,236,804 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011029482 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,927,552 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,673,921 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,921,375 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,624,204 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2017018203 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2019034383 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2021025198 | US Continuation / Sibling | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 1,113,647 | European Counterpart (EP) | View Official Patent → |
Argentum Pharmaceuticals LLC et al. v. Merck Patentgesellschaft Mit Beschrankter Haftung et al.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7834020
Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
|
Filed: 2008-04-28
Issued: 2010-11-16
|
Active (1.4 yrs remaining)
Expires: 2028-04-28
|
|
|
US8193195
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
|
Filed: 2010-11-12
Issued: 2012-06-05
|
Active (4.0 yrs remaining)
Expires: 2030-11-12
|
|
|
US8236804
Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
|
Filed: 2011-05-04
Issued: 2012-08-07
|
Active (4.5 yrs remaining)
Expires: 2031-05-04
|
|
|
US8673921
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
|
Filed: 2013-09-19
Issued: 2014-03-18
|
Active (6.8 yrs remaining)
Expires: 2033-09-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
4
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings